Johnson and Johnson 2011 Annual Report Download - page 58

56 JOHNSON & JOHNSON 2011 ANNUAL REPORT
18. Segments of Business (1) and Geographic Areas
Sales to Customers(2)
(Dollars in Millions) 2011 2010 2009
Consumer —
United States $ 5,151 5,519 6,837
International 9,732 9,071 8,966
Total 14,883 14,590 15,803
Pharmaceutical —
United States 12,386 12,519 13,041
International 11,982 9,877 9,479
Total 24,368 22,396 22,520
Medical Devices and Diagnostics —
United States 11,371 11,412 11,011
International 14,408 13,189 12,563
Total 25,779 24,601 23,574
Worldwide total $65,030 61,587 61,897
Operating Profit Identifiable Assets
(Dollars in Millions) 2011(5) 2010(6) 2009(7) 2011 2010 2009
Consumer $ 2,096 2,342 2,475 $ 24,210 23,753 24,671
Pharmaceutical 6,406 7,086 6,413 23,747 19,961 21,460
Medical Devices and Diagnostics 5,263 8,272 7,694 23,609 23,277 22,853
Total 13,765 17,700 16,582 71,566 66,991 68,984
Less: Expense not allocated to segments(3) 1,404 753 827
General corporate(4) 42,078 35,917 25,698
Worldwide total $12,361 16,947 15,755 $113,644 102,908 94,682
Additions to Property, Depreciation and
Plant & Equipment Amortization
(Dollars in Millions) 2011 2010 2009 2011 2010 2009
Consumer $ 670 526 439 $ 631 532 513
Pharmaceutical 729 508 535 958 912 922
Medical Devices and Diagnostics 1,095 1,113 1,114 1,331 1,270 1,124
Segments total 2,494 2,147 2,088 2,920 2,714 2,559
General corporate 399 237 277 238 225 215
Worldwide total $2,893 2,384 2,365 $3,158 2,939 2,774
Sales to Customers(2) Long-Lived Assets(8)
(Dollars in Millions) 2011 2010 2009 2011 2010 2009
United States $28,908 29,450 30,889 $ 23,529 23,315 22,399
Europe 17,129 15,510 15,934 19,056 16,791 17,347
Western Hemisphere excluding U.S. 6,418 5,550 5,156 3,517 3,653 3,540
Asia-Pacific, Africa 12,575 11,077 9,918 2,163 2,089 1,868
Segments total 65,030 61,587 61,897 48,265 45,848 45,154
General corporate 750 715 790
Other non long-lived assets 64,629 56,345 48,738
Worldwide total $65,030 61,587 61,897 $113,644 102,908 94,682
(1) See Note 1 for a description of the segments in which the Company operates.
(2) Export sales are not significant. In 2011, 2010 and 2009, the Company did not have a customer that represented 10% of total revenues.
(3) Amounts not allocated to segments include interest (income) expense, non-controlling interests and general corporate (income) expense. Included in 2011, was a $0.5 billion expense for
the adjustment to the value of the currency option related to the planned acquisition of Synthes, Inc.
(4) General corporate includes cash and marketable securities.
(5) Includes $1,710 million of net litigation expense, comprised of $1,668 million and $42 million in the Pharmaceutical and Medical Devices and Diagnostics segments, respectively. Includes
$1,600 million of product liability expense, comprised of $73 million in the Pharmaceutical segment and $1,527 million in the Medical Devices and Diagnostics segment. Includes
$656 million of net restructuring expense, comprised of $676 million expense in the Medical Devices and Diagnostics segment and a gain of $20 million in the Pharmaceutical segment.
The Medical Devices and Diagnostics segment also includes $521 million expense for the cost associated with the DePuy ASR™ Hip recall program.
(6) Includes $966 million of net litigation gain, comprised of $333 million expense in the Pharmaceutical segment and a gain of $1,299 million in the Medical Devices and Diagnostics segment.
Includes $569 million of product liability expense, comprised of $114 million in the Pharmaceutical segment and $455 million in the Medical Devices and Diagnostics segment. The Medical
Devices and Diagnostics segment also includes $280 million expense for the cost associated with the DePuy ASR™ Hip recall program.
(7) Includes $1,186 million of restructuring expense, comprised of $369 million, $496 million, and $321 million for the Consumer, Pharmaceutical, and Medical Devices and Diagnostics
segments, respectively. Includes $386 million of fourth quarter net litigation gain, comprised of a $92 million expense in the Pharmaceutical segment and a gain of $478 million in the
Medical Devices and Diagnostics segment.
(8) Long-lived assets include property, plant and equipment, net for 2011, 2010 and 2009 of $14,739, $14,553 and $14,759, respectively, and intangible assets and goodwill, net for 2011, 2010
and 2009 of $34,276, $32,010 and $31,185, respectively.